Quarterly Round-up of Notable Articles (February 2026 to April 2026)

DURATION OF THERAPY FORPSEUDOMONAS AERUGINOSA BACTEREMIA – A POST HOC SUBGROUP ANALYSIS FROM THE BALANCE RANDOMIZED CONTROLLED TRIAL This post hoc subgroup analysis[1] resulted from the landmark Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness trial (BALANCE), a large international randomized controlled trial of 3608 hospitalized adults with bloodstream infections that found no difference between 7 days and 14 days of antibiotic therapy for uncomplicated bacteremia overall (excluding Staphylococcus aureus and infections requiring prolonged treatment). The 157 BALANCE patients with Pseudomonas aeruginosa bacteremia, a subset often regarded as higher risk and frequently treated longer, were the subject of this focused research. Of these, 83 received active therapy for 14 days, whereas 74 received it for 7 days. 29.7% of the 7-day group and 20.5% of the 14-day group had the primary endpoint, 90-day mortality (risk difference 9.2%; 95% confidence interval CI: −4.8 to 23.2), which was not statistically significant. Treatment length did not predict death, but age did, according to multivariable analysis. Although the trial lacked sufficient power to demonstrate noninferiority in this subgroup, rates of relapse and other secondary outcomes were likewise comparable. Comments This study is significant in terms of stewardship because it challenges the conventional belief that Pseudomonas bacteremia necessitates prolonged therapy. Yet, the numerically higher deaths in the group receiving the 7-day course deserve caution as well. This was a small group, and 7-day treatment was associated with more nosocomial infections, more mechanical ventilation, and marginally poorer source control opportunities, each of which might have contributed to poor outcomes irrespective of the antibiotic strategy. The important thing to note here is that the microbiological complexity of this study was much lower compared to Indian practice; the authors mentioned only two MDR pathogens, and there were no difficult-to-treat infections or neutropenic patients. In addition, sources of infection varied considerably and included urinary, respiratory, and catheter-associated sites in addition to unknown sources. Therefore, while advocating a rational approach, this study cannot be directly extrapolated to Indian settings where multidrug resistance is more common and hence, needs more evaluation. ASYMPTOMATIC TUBERCULOSIS ACROSS THE DISEASE SPECTRUM: A SCOPING REVIEW OF EPIDEMIOLOGY, DIAGNOSIS, AND PUBLIC HEALTH IMPLICATIONS This comprehensive scoping review[2] highlights the importance of asymptomatic tuberculosis (formerly known as subclinical TB) and drives home the fact that TB is a disease spectrum rather than a straightforward latent-versus-active binary. According to the authors, asymptomatic TB is defined as microbiologically verified pulmonary TB in people who do not exhibit typical symptoms, including fever, coughing, weight loss, or night sweats. According to the review, approximately 30%–50% of TB cases that are bacteriologically proven may not exhibit any symptoms at the time of diagnosis, which means that symptom-based screening methods may overlook them. Crucially, a sizable percentage of these patients test positive for smears, indicating the possibility of continued transmission even in the face of being clinically quiescent. The early damage to the lungs, inflammation, and radiological changes indicate that it is a pathologically active process rather than a simple colonization. In terms of natural history data, roughly 20%–30% of patients may manifest symptoms in a year or two, but some cases may even spontaneously resolve. Besides stressing the development of novel technologies such as artificial intelligence (AI)-aided chest radiographs, sputum pooling, NAAT testing, and host transcriptomic biomarkers, this study also highlights the challenges associated with diagnosis due to a low bacterial load and sputum acquisition problems. Comments The article is extremely pertinent to India because the current TB programs in India continue to use a symptom-based approach to test patients for TB. Given that coughing continues to be the primary indicator of whether a patient should undergo diagnostic testing, a number of patients who have TB but who do not show symptoms could slip through the cracks of the system. In regions with high prevalence rates and populations vulnerable to TB infection, such as household contacts, diabetics, HIV-infected persons, transplant recipients, prisoners, and slum residents, an aggressive radiological and/or molecular screening approach will definitely enhance the early detection of cases of TB. The study also emphasizes the need for chest X-rays as a triaging measure rather than just depending on symptom questionnaires alone. Although extrapulmonary diseases were not part of this review, at a practical level, one is also aware that silent TB disease is not confined to the lungs because asymptomatic TB-related lymphadenitis exists as well. In India, aggressive asymptomatic screening carries risks of false positivity, overtreatment, and overburdening the current TB control efforts and hence may not be feasible. A 48-WEEK, RANDOMIZED CONTROLLED TRIAL OF DORAVIRINE FOR INDIVIDUALS WITH HIV AND OBESITY ON INTEGRASE INHIBITORS AND TENOFOVIR ALAFENAMIDE: THE DO IT STUDY (ACTG A5391) The 48-week multicenter randomized controlled trial[3] examined whether switching obese HIV-positive patients with INSTIs + TAF/FTC to a doravirine-based regimen will improve metabolic parameters or reverse any weight gain. The median BMI of the 147 individuals in the research was 34.9 kg/m2. Either doravirine + TAF/FTC, doravirine + TDF/FTC, or a change from their existing INSTI + TAF/FTC regimen was randomly assigned to the participants. This patient group was specifically chosen to represent groups that are more likely to gain weight while receiving antiretroviral therapy. In particular, the group comprised 53% Black people, 49% women, and several people who had previously gained significant weight on INSTIs. There was no statistically significant difference in the three arms’ weight changes at week 48, which were − 0.47%, −2.73%, and − 1.84%, respectively. There were no statistically significant changes in waist circumference, lipid levels, insulin resistance, body composition, or bone mineral density. All arms showed viral suppression, and the safety profile was favorable. The authors hence concluded that during a 48-week period, moving from INSTI/TAF to doravirine did not result in appreciable changes in weight or metabolic health. Comments This study undermines the widely held belief that HIV-associated weight gain may be easily reversed by altering antiretroviral medication. Despite specifically enrolling a high-risk cohort most likely to benefit, there was no clinically significant improvement, indicating that obesity in treated HIV is multifactorial and influenced by age, lifestyle, host factors, health recovery effects, and baseline metabolic risk rather than being solely drug-driven. Over half of individuals in all three arms, including those who maintained INSTI therapy, lost weight over time, which is another noteworthy finding. This suggests that behavioral aspects and systematic follow-up may be just as essential as pharmacological substitution. Extrapolation should be done with caution in the Indian context, where dolutegravir-based regimens are common, and this research mostly included bictegravir patients. Biologically speaking, the TDF arm’s numerically larger weight loss is probably due to TDF’s relatively weight-neutral or weight-suppressive profile in comparison to TAF, rather than a genuine anti-obesity impact. Any such advantage must still be weighed against established renal and bone trade-offs. Therefore, rather than relying solely on ART switching, current research recommends comprehensive obesity management. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.